CCB
TGTX icon

Cutter & Co Brokerage’s TG Therapeutics TGTX Stock Holding History

Cutter & Co Brokerage’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,525
Closed -$253K – 320
2021
Q2 		$253K Buy
6,525
+500
+8% +$19.6K 0.06% 237
2021
Q1 		$290K Sell
6,025
-180
-3% -$8.65K 0.07% 217
2020
Q4 		$323K Buy
+6,205
New +$210K 0.08% 185
2020
Q2 		– Sell
-17,550
Closed -$173K – 271
2020
Q1 		$173K Sell
17,550
-1,425
-8% -$18K 0.07% 191
2019
Q4 		$211K Sell
18,975
-965
-5% -$7.34K 0.07% 219
2019
Q3 		$112K Sell
19,940
-350
-2% -$2.44K 0.04% 279
2019
Q2 		$176K Buy
20,290
+3,650
+22% +$27.6K 0.06% 271
2019
Q1 		$134K Sell
16,640
-250
-1% -$1.35K 0.04% 275
2018
Q4 		$69K Sell
16,890
-19,100
-53% -$94.9K 0.03% 256
2018
Q3 		$202K Sell
35,990
-450
-1% -$5.14K 0.07% 254
2018
Q2 		$479K Buy
36,440
+2,215
+6% +$30.5K 0.18% 124
2018
Q1 		$486K Buy
+34,225
New +$437K 0.19% 122

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutter & Co Brokerage's TGTX Position: Q3 2021 in Review

Cutter & Co Brokerage sold out of TG Therapeutics (TGTX) in Q3 2021, closing a stake of 6,525 shares — an estimated $253K sold.

Cutter & Co Brokerage first reported a position in TGTX in Q1 2018 and held it in 12 quarters. The position peaked at $486K in Q1 2018. 222 funds tracked by Wall St. Rank hold TGTX as of Q3 2021.

  • Cutter & Co Brokerage reported no remaining TG Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Cutter & Co Brokerage sold 6,525 TG Therapeutics shares in Q3 2021, an estimated $253K.
  • Cutter & Co Brokerage first reported a position in TG Therapeutics in Q1 2018 and held it in 12 quarters.
  • Cutter & Co Brokerage's TG Therapeutics position peaked at $486K in Q1 2018.
  • 222 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2021.

Based on Cutter & Co Brokerage's 13F filing for Q3 2021, filed 2 Nov 2021.